See the DrugPatentWatch profile for Vorinostat
What dosing sequence is described for vorinostat plus gemtuzumab ozogamicin (GO) in patent materials?
I can’t identify a specific “vorinostat + gemtuzumab ozogamicin dosing sequence” from the information provided. The exact dosing schedule depends on which patent document (publication number/application number) and which claim example (e.g., specific days/cycle structure) you mean.
If you share the patent publication/application number (or paste the relevant claim/example text), I can extract the precise dosing sequence and map it into a clear timeline (e.g., which drug is given first, day-of-cycle numbering, dose units, and whether it’s continuous vs intermittent).
How do patents typically structure schedules for vorinostat with antibody–drug conjugates like GO?
In filings that combine an HDAC inhibitor (vorinostat) with an antibody–drug conjugate (like gemtuzumab ozogamicin), the claimed “sequence” is usually about aligning drug exposure with the ADC’s targeted delivery and internalization. Patent examples often specify:
- A repeating treatment cycle (commonly described as “day 1, day 2…” across a cycle)
- Whether vorinostat is given before the ADC (“pretreatment”) or on alternating days
- Whether the ADC dose occurs once per cycle or multiple times within the cycle
- Washout or spacing between administrations to manage toxicity
However, without the specific patent, I can’t state the exact sequence that “this” patent claims.
Is there more than one vorinostat+GO schedule claimed (e.g., pretreatment vs concurrent)?
Many combination patents include multiple embodiments, such as:
- Vorinostat given for several consecutive days, then GO on a later day
- Vorinostat given shorter “lead-in” period before GO
- Concurrent administration within a defined window
- Dose-escalation cohorts that change the schedule rather than just the dose
To answer your question precisely, I need the exact patent reference you’re working from.
What “sequence” details usually matter for infringement or patentability?
When someone searches for a dosing sequence in patent materials, they typically look for:
- Timing relationship (e.g., “vorinostat before GO” with a specific day offset)
- Duration of vorinostat exposure before the GO dose
- Whether the schedule is required by the claim (not just described in examples)
- Whether the claim is defined by dose levels, patient population, or both
Again, the answer is document-specific.
What I need from you to produce the exact dosing sequence answer
Reply with any of the following:
- The patent publication number (e.g., WO…, EP…, US…) or application number
- A link to the patent
- The text of the section that contains “dosing sequence” (claims or Example schedule)
Then I’ll extract the schedule verbatim into a clean day-by-day sequence and cite the exact parts of the document.
Sources
No patent document was provided, so there are no sources to cite yet.